Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate efficacy of eplerenone, a new drug for the treatment of acute heart failure while protecting myocardium (a randomized, double-blind, placebo-controlled study)

Next Previous
Trial Profile

A clinical study to evaluate efficacy of eplerenone, a new drug for the treatment of acute heart failure while protecting myocardium (a randomized, double-blind, placebo-controlled study)

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 09 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Acute heart failure
  • Focus Therapeutic Use
  • Acronyms EARLIER001

Most Recent Events

  • 03 Oct 2024 Results assessing the adverse events of eplerenone in acute-heart-failure patients were published in the International Journal of Cardiology.
  • 13 Nov 2023 Results of Sub-Analysis assessing effect of Eplerenone on Cardiac Reverse Remodeling in Patients With Acute Heart Failure, presented at the American Heart Association Scientific Sessions 2023
  • 19 Sep 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top